Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Dry Eye Disease Market

Dry Eye Disease Market Trends

  • Report ID: GMI4299
  • Published Date: Jul 2023
  • Report Format: PDF

Dry Eye Disease Market Trends

Increasing prevalence of eye-related diseases is anticipated to drive the market share. The global population is experiencing a significant increase in the aging demographic. With age, the risk of developing eye-related diseases, including dry eye disease, increases significantly. The prevalence of dry eye disease tends to be higher in older individuals. For instance, according to an article published by the Karger Journal, in 2022 the prevalence rate of dry eye disease among people aged above 50 years in Asia was estimated to be around 50% and is expected in increase in the coming years.
 

This high prevalence rate is set to augment the demand for dry eye disease treatment products globally. Prolonged screen time and decreased blink rate associated with digital device use can contribute to dry eye symptoms. The increasing dependence on digital devices has resulted in a higher prevalence of dry eye disease among all age groups.
 

Dry eye disease often coexists with other systemic conditions, such as autoimmune diseases, diabetes, and thyroid disorders. The rising prevalence of these comorbidities contributes to the increasing prevalence of dry eye disease. There has been a growing awareness and understanding of dry eye disease among both healthcare professionals and the general population. Increased knowledge about the condition has led to improved diagnosis rates. Eye care professionals are better equipped to identify and diagnose dry eye disease, leading to a higher reported prevalence.

Authors: Mariam Faizullabhoy , Shishanka Wangnoo

Frequently Asked Questions (FAQ) :

The global market for dry eye disease was valued at over USD 6 billion in 2022 and is projected to reach around USD 12.3 billion by 2032, owing to increasing prevalence of dry eye disease and associated ailments.

The cyclosporine segment accounted for over 35% market share in 2022. Cyclosporine is an immunomodulatory medication that has been found to provide several benefits in the diagnosis and treatment of dry eye disease.

North America dry eye disease market was valued at USD 2.4 billion in 2022 and will continue upward growth trend through 2032, ascribed to an increase in the number of patients suffering from dry eye disease, and expanding elderly population in the region.

AbbVie, Inc., AFT Pharmaceuticals, Alcon, Bausch & Lomb, Johnson & Johnson Services, Inc., Novartis AG, OASIS Medical, Otsuka Pharmaceutical Co., Ltd., Oyster Point Pharma, Inc., and Santen Pharmaceutical Co., Ltd. among others.

Dry Eye Disease Market Scope

Buy Now


Premium Report Details

  • Base Year: 2022
  • Companies covered: 15
  • Tables & Figures: 351
  • Countries covered: 30
  • Pages: 190
 Download Free Sample